News
-
-
-
-
-
-
PRESS RELEASE
Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi
Jaguar Health, Inc. provides updates on rare disease program for crofelemer, focusing on intestinal failure treatment milestones, Orphan Drug Designation, and global development efforts -
-
PRESS RELEASE
BaFin reduces SREP capital requirements (P2R) for flatexDEGIRO Group by 25 basis points to 2.50%
BaFin reduces SREP capital requirements for flatexDEGIRO Group by 25 basis points. flatexDEGIRO SE serves over 3.5 million customers in 16 countries with €90 billion in assets under custody -
-